Opportunities this week:

GSK experienced a mixed performance in 2024, with its stock rising by 21.5% until May before declining by 22% in the second half, resulting in a total return of -3.5% for the year. Despite this, the outlook remains positive, with a target price of 1920p.
Flutter reduced its FY24 guidance for both revenues and profits in the US, due to historically customer-friendly results, however, the impacts of this are not expected to have any material impact on the company’s 2025 outlook. BUY PTY: $300.
Glanbia is currently valued at or near a 10-year low valuation on both PE and EV/EBITDA. As such, we view this as a very attractive entry point for investors. BUY PT: €19.40.